Vmn2r7 Inhibitors
Vmn2r7 can interfere with various cellular processes essential for the proper function of this protein. Olomoucine, as a cyclin-dependent kinase inhibitor, can halt cell cycle progression, which can be vital for the synthesis and trafficking of membrane proteins, including Vmn2r7. If the movement of Vmn2r7 to the cell surface is impeded, its functionality can be significantly compromised. Genistein, by inhibiting tyrosine kinase activity, can disrupt phosphorylation events crucial for the activation and signaling of Vmn2r7. Similarly, Gö6976, a protein kinase C inhibitor, can prevent the phosphorylation that may be required for the activation or regulation of Vmn2r7, thus potentially reducing its activity.
Brefeldin A can disrupt the trafficking of proteins like Vmn2r7 by inhibiting ADP-ribosylation factor necessary for vesicle formation within the Golgi apparatus. Tunicamycin's inhibition of N-linked glycosylation can lead to the production of a misfolded Vmn2r7 protein, which can be unable to function correctly. Concanamycin A, by inhibiting the V-ATPase proton pump, can alter the acidification inside vesicles, potentially affecting the sorting or maturation of Vmn2r7. In the realm of signal transduction, NF449 can inhibit the Gs-alpha subunit of G-proteins, which can lead to reduced signaling capabilities of Vmn2r7. PD 98059 and SB 203580 target the MAPK/ERK and p38 MAP kinase pathways, respectively, and by doing so, can decrease the phosphorylation and activation of proteins involved in Vmn2r7 signaling. LY294002 and Wortmannin, both PI3 kinase inhibitors, can interfere with the PI3K/Akt pathway, which can be crucial for the activity of Vmn2r7. Lastly, U73122's inhibition of phospholipase C can prevent the production of secondary messengers from PIP2, which are potentially important for the signaling of Vmn2r7.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a cyclin-dependent kinase inhibitor that can inhibit cell cycle progression. Given that cell cycle control is crucial for the synthesis and trafficking of membrane proteins like Vmn2r7, the inhibition of these kinases may lead to reduced functionality of Vmn2r7 due to impaired transport or reduced surface expression. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can disrupt various signaling pathways. As phosphorylation by tyrosine kinases is an important regulatory mechanism for many receptors, the inhibition could prevent proper Vmn2r7 function by disrupting its activation or downstream signaling. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF), which plays a role in vesicle formation in the Golgi apparatus. By inhibiting ARF, Brefeldin A could disrupt the trafficking of Vmn2r7 to the membrane, effectively reducing its functional presence. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, a process that could be essential for the proper folding and function of Vmn2r7. By preventing glycosylation, Tunicamycin could result in a misfolded and non-functional Vmn2r7 protein. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
Gö6976 is a protein kinase C (PKC) inhibitor. If Vmn2r7 function is regulated by PKC-mediated phosphorylation, inhibition of PKC could reduce the receptor's activity by preventing necessary phosphorylation events. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $65.00 $162.00 $650.00 $2550.00 | 109 | |
Concanamycin A is a specific inhibitor of the V-ATPase proton pump, which is essential for acidifying intracellular vesicles. Acidification may be necessary for the proper sorting or maturation of Vmn2r7, and its inhibition could lead to the receptor's dysfunction. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $199.00 $460.00 $1479.00 | 1 | |
NF449 is a potent and selective inhibitor of Gs-alpha subunit of G-proteins. If Vmn2r7 signals through the Gs protein pathway, inhibition of this subunit could lead to reduced signaling and thereby inhibit Vmn2r7 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. Inhibition of MEK could lead to decreased phosphorylation and activation of downstream proteins that may be required for Vmn2r7 signaling or expression on the cell surface. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is an inhibitor of p38 MAP kinase, which may play a role in Vmn2r7 signaling if this kinase is part of Vmn2r7's signaling pathway. Inhibition of p38 MAP kinase could lead to a decrease in Vmn2r7-mediated signal transduction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3 kinase inhibitor, which could disrupt the PI3K/Akt signaling pathway. If Vmn2r7 relies on this pathway for proper functioning, inhibition by LY294002 could lead to a reduction in Vmn2r7 activity. | ||||||